AT
The startup develops a medical therapy technology that utilizes bio-mimicking efferocytosis to enhance the removal of apoptotic cells by immature dendritic cells. This approach enables targeted treatments for autoimmune disorders such as type 1 diabetes, multiple sclerosis, and celiac disease.
Updated 3 months ago
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a medical therapy technology that utilizes bio-mimicking efferocytosis to enhance the removal of apoptotic cells by immature dendritic cells. This approach enables targeted treatments for autoimmune disorders such as type 1 diabetes, multiple sclerosis, and celiac disease.